Atrinsic (NASDAQ:PTIX) Shares Up 6.2% – Here’s What Happened

Atrinsic Inc. (NASDAQ:PTIX) shot up 6.2% during mid-day trading on Thursday . The stock traded as high as $0.6583 and last traded at $0.6583. 34,356 shares were traded during trading, a decline of 94% from the average session volume of 549,151 shares. The stock had previously closed at $0.62.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on PTIX shares. Weiss Ratings reiterated a “sell (e)” rating on shares of Atrinsic in a report on Monday, December 29th. Wall Street Zen upgraded Atrinsic from a “sell” rating to a “hold” rating in a research note on Saturday, September 13th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Sell”.

Atrinsic Trading Up 6.2%

The stock has a market capitalization of $1.27 million, a P/E ratio of -0.08 and a beta of 0.51. The business’s fifty day simple moving average is $1.67 and its two-hundred day simple moving average is $2.77.

Atrinsic (NASDAQ:PTIX) last announced its quarterly earnings data on Wednesday, November 26th. The company reported ($0.47) EPS for the quarter.

Atrinsic Company Profile

Protagenic Therapeutics, Inc, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc is headquartered in New York, New York.